Carousel Capital has suspended the sale process for Palmetto Infusion Services, multiple sources tell Axios.
Why it matters: While investors are eager to build out ambulatory infusion center networks to disrupt a market historically dominated by hospitals, this Southeast-centric player is punting sale plans to a future date.
Details: As is often the case, a mismatch in buyer and seller value expectations contributed to the shelved process, sources say.
Catch up quick: Carousel, three years into its investment, engaged Raymond James early this year to explore options for Palmetto.
Be smart: Investors' increasing enthusiasm around AIC organizations reflects the large innovation opportunity in what is a massive and growing market.
What they're saying: Whereas some AICs are prioritizing a high-end patient experience that comes with luxury private rooms or smaller, intimate sites, Palmetto tends to have larger clinics — which might better position it for any potential reimbursement cuts in the future, one investor notes.
đź‘€ What else we're watching: KabaFusion, an intravenous immunoglobulin (IVIG)-focused in-home infusion platform, whose deal we hear is around the corner. Carousel, Palmetto and Raymond James did not immediately return requests for comment.